×
Taysha Gene Therapies EBIT 2020-2024 | TSHA
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Taysha Gene Therapies ebit from 2020 to 2024. Ebit can be defined as earnings before interest and taxes.
View More
Taysha Gene Therapies EBIT 2020-2024 | TSHA
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Taysha Gene Therapies ebit from 2020 to 2024. Ebit can be defined as earnings before interest and taxes.
Related Stocks
Company Name
Market
Cap
Teva Pharmaceutical Industries (TEVA)
$20.1B
Dr Reddy's Laboratories (RDY)
$13.1B
BridgeBio Pharma (BBIO)
$5B
Bausch Health Cos (BHC)
$3B
Amphastar Pharmaceuticals (AMPH)
$2.4B
Supernus Pharmaceuticals (SUPN)
$1.8B
Personalis (PSNL)
$315M
Assembly Biosciences (ASMB)
$117M
Acasti Pharma (ACST)
$28M
Sol-Gel Technologies (SLGL)
$20M
Evoke Pharma (EVOK)
$4M
Teligent (TLGT)
$0M